(Reuters) - The European drugs watchdog said the withdrawal of
garenoxacin followed a request for additional information, to
which the company was unable to respond within the permitted
timeframe.
Read more at Reuters.com Government Filings News
garenoxacin followed a request for additional information, to
which the company was unable to respond within the permitted
timeframe.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment